메뉴 건너뛰기




Volumn 22, Issue 4, 2016, Pages 256-262

Prognostic Value of Galectin-3 for Adverse Outcomes in Chronic Heart Failure

Author keywords

Biomarker; ejection fraction; risk stratification; ventricular function

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GALECTIN 3; HYDRALAZINE; NITRIC ACID DERIVATIVE; TOLL LIKE RECEPTOR 2; TROPONIN I; BIOLOGICAL MARKER; GALECTIN-3, HUMAN;

EID: 84951923195     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2015.10.022     Document Type: Article
Times cited : (45)

References (32)
  • 1
    • 84922381210 scopus 로고    scopus 로고
    • Heart disease and stroke statistics—2015 update: a report from the American Heart Association
    • 1 Mozaffarian, D., Benjamin, E.J., Go, A.S., Arnett, D.K., Blaha, M.J., Cushman, M., et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation 131 (2015), e29–322, 10.1161/CIR.0000000000000152.
    • (2015) Circulation , vol.131 , pp. e29-322
    • Mozaffarian, D.1    Benjamin, E.J.2    Go, A.S.3    Arnett, D.K.4    Blaha, M.J.5    Cushman, M.6
  • 2
    • 0033994772 scopus 로고    scopus 로고
    • The economic burden of heart failure
    • 2 O'Connell, J.B., The economic burden of heart failure. Clin Cardiol 23 (2000), III-6–10, 10.1002/clc.4960231503.
    • (2000) Clin Cardiol , vol.23 , pp. III-6-10
    • O'Connell, J.B.1
  • 3
    • 6444239869 scopus 로고    scopus 로고
    • Ongoing myocardial injury in stable severe heart failure: value of cardiac troponin T monitoring for high-risk patient identification
    • 3 Perna, E.R., Macin, S.M., Canella, J.P., Augier, N., Stival, J.L., Cialzeta, J.R., et al. Ongoing myocardial injury in stable severe heart failure: value of cardiac troponin T monitoring for high-risk patient identification. Circulation 110 (2004), 2376–2382, 10.1161/01.CIR.0000145158.33801.F3.
    • (2004) Circulation , vol.110 , pp. 2376-2382
    • Perna, E.R.1    Macin, S.M.2    Canella, J.P.3    Augier, N.4    Stival, J.L.5    Cialzeta, J.R.6
  • 4
    • 84875766051 scopus 로고    scopus 로고
    • B-Type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction
    • 4 van Veldhuisen, D.J., Linssen, G.C., Jaarsma, T., van Gilst, W.H., Hoes, A.W., Tijssen, J.G., et al. B-Type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol 61 (2013), 1498–1506, 10.1016/j.jacc.2012.12.044.
    • (2013) J Am Coll Cardiol , vol.61 , pp. 1498-1506
    • van Veldhuisen, D.J.1    Linssen, G.C.2    Jaarsma, T.3    van Gilst, W.H.4    Hoes, A.W.5    Tijssen, J.G.6
  • 5
    • 79955943158 scopus 로고    scopus 로고
    • High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure
    • 5 Ky, B., French, B., McCloskey, K., Rame, J.E., McIntosh, E., Shahi, P., et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail 4 (2011), 180–187, 10.1161/CIRCHEARTFAILURE.110.958223.
    • (2011) Circ Heart Fail , vol.4 , pp. 180-187
    • Ky, B.1    French, B.2    McCloskey, K.3    Rame, J.E.4    McIntosh, E.5    Shahi, P.6
  • 6
    • 1542343883 scopus 로고    scopus 로고
    • Extracellular functions of galectin-3
    • 6 Ochieng, J., Furtak, V., Lukyanov, P., Extracellular functions of galectin-3. Glycoconj J 19 (2004), 527–535, 10.1023/B:GLYC.0000014082.99675.2f.
    • (2004) Glycoconj J , vol.19 , pp. 527-535
    • Ochieng, J.1    Furtak, V.2    Lukyanov, P.3
  • 7
    • 33745006606 scopus 로고    scopus 로고
    • Galectin-3: an open-ended story
    • 7 Dumic, J., Dabelic, S., Flogel, M., Galectin-3: an open-ended story. Biochim Biophys Acta 1760 (2006), 616–635, 10.1016/j.bbagen.2005.12.020.
    • (2006) Biochim Biophys Acta , vol.1760 , pp. 616-635
    • Dumic, J.1    Dabelic, S.2    Flogel, M.3
  • 9
    • 61949375975 scopus 로고    scopus 로고
    • N-Acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin
    • 9 Liu, Y.H., d'Ambrosio, M., Liao, T.D., Peng, H., Rhaleb, N.E., Sharma, U., et al. N-Acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol 296 (2009), H404–12, 10.1152/ajpheart.00747.2008.
    • (2009) Am J Physiol Heart Circ Physiol , vol.296 , pp. H404-12
    • Liu, Y.H.1    d'Ambrosio, M.2    Liao, T.D.3    Peng, H.4    Rhaleb, N.E.5    Sharma, U.6
  • 10
    • 77449109919 scopus 로고    scopus 로고
    • Galectin-3 in cardiac remodeling and heart failure
    • 10 de Boer, R.A., Yu, L., van Veldhuisen, D.J., Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep 7 (2010), 1–8, 10.1007/s11897-010-0004-x.
    • (2010) Curr Heart Fail Rep , vol.7 , pp. 1-8
    • de Boer, R.A.1    Yu, L.2    van Veldhuisen, D.J.3
  • 11
    • 20844462878 scopus 로고    scopus 로고
    • Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction
    • 11 Sharma, U.C., Pokharel, S., van Brakel, T.J., van Berlo, J.H., Cleutjens, J.P., Schroen, B., et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110 (2004), 3121–3128, 10.1161/01.CIR.0000147181.65298.4D.
    • (2004) Circulation , vol.110 , pp. 3121-3128
    • Sharma, U.C.1    Pokharel, S.2    van Brakel, T.J.3    van Berlo, J.H.4    Cleutjens, J.P.5    Schroen, B.6
  • 12
    • 84902298336 scopus 로고    scopus 로고
    • Comprehensive review of the prognostic value of galectin-3 in heart failure
    • 12 Coburn, E., Frishman, W., Comprehensive review of the prognostic value of galectin-3 in heart failure. Cardiol Rev 22 (2014), 171–175, 10.1097/CRD.0000000000000013.
    • (2014) Cardiol Rev , vol.22 , pp. 171-175
    • Coburn, E.1    Frishman, W.2
  • 13
    • 79960350455 scopus 로고    scopus 로고
    • Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival
    • 13 Tang, W.H., Shrestha, K., Shao, Z., Borowski, A.G., Troughton, R.W., Thomas, J.D., et al. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol 108 (2011), 385–390, 10.1016/j.amjcard.2011.03.056.
    • (2011) Am J Cardiol , vol.108 , pp. 385-390
    • Tang, W.H.1    Shrestha, K.2    Shao, Z.3    Borowski, A.G.4    Troughton, R.W.5    Thomas, J.D.6
  • 14
    • 79960555230 scopus 로고    scopus 로고
    • Galectin-3 in heart failure: high levels are associated with all-cause mortality
    • 14 Ueland, T., Aukrust, P., Broch, K., Aakhus, S., Skardal, R., Muntendam, P., et al. Galectin-3 in heart failure: high levels are associated with all-cause mortality. Int J Cardiol 150 (2011), 361–364, 10.1016/j.ijcard.2011.05.081.
    • (2011) Int J Cardiol , vol.150 , pp. 361-364
    • Ueland, T.1    Aukrust, P.2    Broch, K.3    Aakhus, S.4    Skardal, R.5    Muntendam, P.6
  • 15
    • 84555204713 scopus 로고    scopus 로고
    • Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial
    • 15 Lopez-Andrès, N., Rossignol, P., Iraqi, W., Fay, R., Nuée, J., Ghio, S., et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail 14 (2012), 74–81, 10.1093/eurjhf/hfr151.
    • (2012) Eur J Heart Fail , vol.14 , pp. 74-81
    • Lopez-Andrès, N.1    Rossignol, P.2    Iraqi, W.3    Fay, R.4    Nuée, J.5    Ghio, S.6
  • 16
    • 77954658143 scopus 로고    scopus 로고
    • Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the Deal-HF study
    • 16 Lok, D.J., van der Meer, P., de la Porte, P.W., Lipsic, E., van Wijngaarden, J., Hillege, H.L., et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the Deal-HF study. Clin Res Cardiol 99 (2010), 323–328, 10.1007/s00392-010-0125-y.
    • (2010) Clin Res Cardiol , vol.99 , pp. 323-328
    • Lok, D.J.1    van der Meer, P.2    de la Porte, P.W.3    Lipsic, E.4    van Wijngaarden, J.5    Hillege, H.L.6
  • 17
    • 84859639923 scopus 로고    scopus 로고
    • Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study
    • 17 Felker, G.M., Fiuzat, M., Shaw, L.K., Clare, R., Whellan, D.J., Bettari, L., et al. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail 5 (2012), 72–88, 10.1161/CIRCHEARTFAILURE.111.963637.
    • (2012) Circ Heart Fail , vol.5 , pp. 72-88
    • Felker, G.M.1    Fiuzat, M.2    Shaw, L.K.3    Clare, R.4    Whellan, D.J.5    Bettari, L.6
  • 19
    • 84901658442 scopus 로고    scopus 로고
    • Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure
    • 19 Ahmad, T., Fiuzat, M., Neely, B., Neely, M.L., Pencina, M.J., Kraus, W.E., et al. Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure. JACC Heart Fail 2 (2014), 260–268, 10.1016/j.jchf.2013.12.004.
    • (2014) JACC Heart Fail , vol.2 , pp. 260-268
    • Ahmad, T.1    Fiuzat, M.2    Neely, B.3    Neely, M.L.4    Pencina, M.J.5    Kraus, W.E.6
  • 20
    • 84892415130 scopus 로고    scopus 로고
    • Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3
    • 20 Bayes-Genis, A., de Antonio, M., Vila, J., Peñafiel, J., Galán, A., Barallat, J., et al. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. J Am Coll Cardiol 63 (2014), 158–166, 10.1016/j.jacc.2013.07.087.
    • (2014) J Am Coll Cardiol , vol.63 , pp. 158-166
    • Bayes-Genis, A.1    de Antonio, M.2    Vila, J.3    Peñafiel, J.4    Galán, A.5    Barallat, J.6
  • 21
    • 78651387589 scopus 로고    scopus 로고
    • Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction
    • 21 de Boer, R.A., Lok, D.J., Jaarsma, T., van der Meer, P., Voors, A.A., Hillege, H.L., et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 43 (2011), 60–68, 10.3109/07853890.2010.538080.
    • (2011) Ann Med , vol.43 , pp. 60-68
    • de Boer, R.A.1    Lok, D.J.2    Jaarsma, T.3    van der Meer, P.4    Voors, A.A.5    Hillege, H.L.6
  • 22
    • 84902258897 scopus 로고    scopus 로고
    • Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes
    • 22 Basuray, A., French, B., Ky, B., Vorovich, E., Olt, C., Sweitzer, N.K., et al. Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes. Circulation 129 (2014), 2380–2387, 10.1161/CIRCULATIONAHA.113.006855.
    • (2014) Circulation , vol.129 , pp. 2380-2387
    • Basuray, A.1    French, B.2    Ky, B.3    Vorovich, E.4    Olt, C.5    Sweitzer, N.K.6
  • 23
    • 84897017376 scopus 로고    scopus 로고
    • Analytical evaluation of the automated galectin-3 assay on the Abbott Architect immunoassay instruments
    • 23 Gaze, D.C., Prante, C., Dreier, J., Knabbe, C., Collet, C., Launay, J.M., et al. Analytical evaluation of the automated galectin-3 assay on the Abbott Architect immunoassay instruments. Clin Chem Lab Med 52 (2014), 919–926, 10.1515/cclm-2013-0942.
    • (2014) Clin Chem Lab Med , vol.52 , pp. 919-926
    • Gaze, D.C.1    Prante, C.2    Dreier, J.3    Knabbe, C.4    Collet, C.5    Launay, J.M.6
  • 24
    • 84860797764 scopus 로고    scopus 로고
    • Multiple biomarkers for risk prediction in chronic heart failure
    • 24 Ky, B., French, B., Levy, W.C., Sweitzer, N.K., Fang, J.C., Wu, A.H., et al. Multiple biomarkers for risk prediction in chronic heart failure. Circ Heart Fail 5 (2012), 183–190, 10.1161/CIRCHEARTFAILURE.111.965020.
    • (2012) Circ Heart Fail , vol.5 , pp. 183-190
    • Ky, B.1    French, B.2    Levy, W.C.3    Sweitzer, N.K.4    Fang, J.C.5    Wu, A.H.6
  • 25
    • 0033936550 scopus 로고    scopus 로고
    • Time-dependent ROC curves for censored survival data and a diagnostic marker
    • 25 Heagerty, P.J., Lumley, T., Pepe, M.S., Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 56 (2000), 337–344, 10.1111/j.0006-341X.2000.00337.x.
    • (2000) Biometrics , vol.56 , pp. 337-344
    • Heagerty, P.J.1    Lumley, T.2    Pepe, M.S.3
  • 26
    • 84866729958 scopus 로고    scopus 로고
    • Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community
    • 26 Ho, J.E., Liu, C., Lyass, A., Courchesne, P., Pencina, M.J., Vasan, R.S., et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol 60 (2012), 1249–1256, 10.1016/j.jacc.2012.04.053.
    • (2012) J Am Coll Cardiol , vol.60 , pp. 1249-1256
    • Ho, J.E.1    Liu, C.2    Lyass, A.3    Courchesne, P.4    Pencina, M.J.5    Vasan, R.S.6
  • 27
    • 84922956288 scopus 로고    scopus 로고
    • Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial
    • 27 Edelmann, F., Holzendorf, V., Wachter, R., Nolte, K., Schmidt, A.G., Kraigher-Krainer, E., et al. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. Eur J Heart Fail 17 (2015), 214–223, 10.1002/ejhf.203.
    • (2015) Eur J Heart Fail , vol.17 , pp. 214-223
    • Edelmann, F.1    Holzendorf, V.2    Wachter, R.3    Nolte, K.4    Schmidt, A.G.5    Kraigher-Krainer, E.6
  • 28
    • 84897534300 scopus 로고    scopus 로고
    • Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction
    • 28 Mohammed, S.F., Mirzoyev, S.A., Edwards, W.D., Dogan, A., Grogan, D.R., Dunlay, S.M., et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail 2 (2014), 113–122, 10.1016/j.jchf.2013.11.004.
    • (2014) JACC Heart Fail , vol.2 , pp. 113-122
    • Mohammed, S.F.1    Mirzoyev, S.A.2    Edwards, W.D.3    Dogan, A.4    Grogan, D.R.5    Dunlay, S.M.6
  • 29
    • 0037432301 scopus 로고    scopus 로고
    • Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT)
    • 29 Anand, I.S., Fisher, L.D., Chiang, Y.T., Latini, R., Masson, S., Maggioni, A.P., et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107 (2003), 1278–1283, 10.1161/01.CIR.0000054164.99881.00.
    • (2003) Circulation , vol.107 , pp. 1278-1283
    • Anand, I.S.1    Fisher, L.D.2    Chiang, Y.T.3    Latini, R.4    Masson, S.5    Maggioni, A.P.6
  • 30
    • 70349983577 scopus 로고    scopus 로고
    • Profiles of serial changes in cardiac troponin T concentrations and outcome in ambulatory patients with chronic heart failure
    • 30 Miller, W.L., Hartman, K.A., Burritt, M.F., Grill, D.E., Jaffe, A.S., Profiles of serial changes in cardiac troponin T concentrations and outcome in ambulatory patients with chronic heart failure. J Am Coll Cardiol 54 (2009), 1715–1721, 10.1016/j.jacc.2009.07.025.
    • (2009) J Am Coll Cardiol , vol.54 , pp. 1715-1721
    • Miller, W.L.1    Hartman, K.A.2    Burritt, M.F.3    Grill, D.E.4    Jaffe, A.S.5
  • 31
    • 84922751256 scopus 로고    scopus 로고
    • Letter by Psaty et al regarding article, “Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes”
    • 31 Psaty, B.M., Shah, S.J., Gottdiener, J., Letter by Psaty et al regarding article, “Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes”. Circulation, 131, 2015, e343, 10.1161/CIRCULATIONAHA.114.012243.
    • (2015) Circulation , vol.131 , pp. e343
    • Psaty, B.M.1    Shah, S.J.2    Gottdiener, J.3
  • 32
    • 84922702448 scopus 로고    scopus 로고
    • Response to letter regarding article, “Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes
    • 32 Basuray, A., French, B., Ky, B., Vorovich, E., Olt, C., Sweitzer, N., et al. Response to letter regarding article, “Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes. Circulation, 131, 2015, e344, 10.1161/CIRCULATIONAHA.114.012888.
    • (2015) Circulation , vol.131 , pp. e344
    • Basuray, A.1    French, B.2    Ky, B.3    Vorovich, E.4    Olt, C.5    Sweitzer, N.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.